NC Medicaid
Pharmacy Prior Approval Request
Immunomodulators: Xeljanz

Beneficiary Information

1. Beneficiary Last Name: _____2. First Name: _____
3. Beneficiary ID #: _____ 4. Beneficiary Date of Birth: _____ 5. Beneficiary Gender:_____

Prescriber Information

6. Prescribing Provider NPI #: _____
7. Requester Contact Information - Name: _____ Phone #: _____ Ext. _____

Drug Information

8. Drug Name: _____ 9. Strength: _____ 10. Quantity Per 30 Days:_____
11. Length of Therapy (in days): ☐ up to 30 Days ☐ 60 Days ☐ 90 Days ☐ 120 Days ☐ 180 Days ☐ 365 Days ☐ Other _____

Clinical Information

Request for Ankylosing Spondylitis (Xeljanz tablets)

1. Does the beneficiary have a diagnosis of Ankylosing Spondylitis? ☐ **Yes** ☐ **No**
2. Is the beneficiary not on another injectable biologic immunomodulator? ☐ **Yes** ☐ **No**
3. Has the beneficiary individual risks and benefits been considered prior to initiating or continuing therapy in those at higher risk for malignancy and/or major adverse cardiovascular events (MACE)? ☐ **Yes** ☐ **No**
4. Has the beneficiary been considered **NOT** to be at high risk for thrombosis? ☐ **Yes** ☐ **No**
5. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? ☐ **Yes** ☐ **No**
6. Has the beneficiary been tested with Hep B SAG and Core Ab? ☐ **Yes** ☐ **No**
7. Will the beneficiary **NOT** receive live vaccines during therapy? ☐ **Yes** ☐ **No**
8. Has the beneficiary tried at least one Tumor Necrosis Factor Blocker with inadequate response or is unable to take these therapies due to intolerance or contraindications? ☐ **Yes** ☐ **No**
9. Has the beneficiary had a trial and failure of Cosentyx, Enbrel or Humira or a clinical reason beneficiary cannot try Cosentyx, Enbrel or Humira? ☐ **Yes** ☐ **No**

Request for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Xeljanz tablets, Xeljanz oral solution)

1. Does the beneficiary have a diagnosis of Polyarticular Juvenile Idiopathic Arthritis? ☐ **Yes** ☐ **No**
2. Is the beneficiary not on another injectable biologic immunomodulator? ☐ **Yes** ☐ **No**
3. Has the beneficiary individual risks and benefits been considered prior to initiating or continuing therapy in those at higher risk for malignancy and/or major adverse cardiovascular events (MACE)? ☐ **Yes** ☐ **No**
4. Has the beneficiary been considered **NOT** to be at high risk for thrombosis? ☐ **Yes** ☐ **No**
5. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? ☐ **Yes** ☐ **No**
6. Has the beneficiary been tested with Hep B SAG and Core Ab? ☐ **Yes** ☐ **No**
7. Will the beneficiary **NOT** receive live vaccines during therapy? ☐ **Yes** ☐ **No**
8. Has the beneficiary tried at least one Tumor Necrosis Factor Blocker with inadequate response or is unable to take these therapies due to intolerance or contraindications? ☐ **Yes** ☐ **No**

9. Has the beneficiary had a trial and failure of Enbrel or Humira or a clinical reason beneficiary cannot try Enbrel or Humira? ☐ **Yes** ☐ **No**

Request for Psoriatic Arthritis (Xeljanz tablets)

1. Does the beneficiary have a documented definitive diagnosis of Psoriatic Arthritis? ☐ **Yes** ☐ **No**
2. Is the beneficiary 18 years of age or older? ☐ **Yes** ☐ **No**
3. Is the beneficiary not on another injectable biologic immunomodulator? ☐ **Yes** ☐ **No**
4. Has the beneficiary individual risks and benefits been considered prior to initiating or continuing therapy in those at higher risk for malignancy and/or major adverse cardiovascular events (MACE)? ☐ **Yes** ☐ **No**
5. Has the beneficiary been considered **NOT** to be at high risk for thrombosis? ☐ **Yes** ☐ **No**
6. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? ☐ **Yes** ☐ **No**
7. Has the beneficiary been tested with Hep B SAG and Core Ab? ☐ **Yes** ☐ **No**
8. Will the beneficiary **NOT** receive live vaccines during therapy? ☐ **Yes** ☐ **No**
9. Does the beneficiary have a documented inadequate response, intolerance or contraindication to at least one Tumor Necrosis Factor Blocker? ☐ **Yes** ☐ **No**
10. Has the beneficiary had a trial and failure of Cosentyx, Enbrel or Humira or a clinical reason beneficiary cannot try Cosentyx, Enbrel or Humira? ☐ **Yes** ☐ **No**

Request for Rheumatoid Arthritis (Xeljanz tablets)

1. Does the beneficiary have a diagnosis of Rheumatoid Arthritis? ☐ **Yes** ☐ **No**
2. Is the beneficiary not on another injectable biologic immunomodulator? ☐ **Yes** ☐ **No**
3. Has the beneficiary individual risks and benefits been considered prior to initiating or continuing therapy in those at higher risk for malignancy and/or major adverse cardiovascular events (MACE)? ☐ **Yes** ☐ **No**
4. Has the beneficiary been considered **NOT** to be at high risk for thrombosis? ☐ **Yes** ☐ **No**
5. Has the beneficiary been considered and screened for the presence of latent tuberculosis? ☐ **Yes** ☐ **No**
6. Has the beneficiary been tested with Hep B SAG and Core Ab? ☐ **Yes** ☐ **No**
7. Will the beneficiary **NOT** receive live vaccines during therapy? ☐ **Yes** ☐ **No**
8. Has the beneficiary experienced a therapeutic failure/inadequate response with at least one Tumor Necrosis Factor Blocker? ☐ **Yes** ☐ **No**
9. Is the beneficiary unable to receive Necrosis Factor Blocker due to contraindications or intolerabilities? ☐ **Yes** ☐ **No**
10. Has the beneficiary had a trial and failure of Enbrel or Humira or a clinical reason beneficiary cannot try Enbrel or Humira? ☐ **Yes** ☐ **No**

Request for Ulcerative colitis (Adult) (Xeljanz tablets)

1. Does the beneficiary have a diagnosis ulcerative colitis? ☐ **Yes** ☐ **No**
2. Is the beneficiary not on another injectable biologic immunomodulator? ☐ **Yes** ☐ **No**
3. Has the beneficiary individual risks and benefits been considered prior to initiating or continuing therapy in those at higher risk for malignancy and/or major adverse cardiovascular events (MACE)? ☐ **Yes** ☐ **No**
4. Has the beneficiary been considered **NOT** to be at high risk for thrombosis? ☐ **Yes** ☐ **No**
5. Has the beneficiary been considered and screened for the presence of latent tuberculosis? ☐ **Yes** ☐ **No**
6. Has the beneficiary been tested with Hep B SAG and Core Ab? ☐ **Yes** ☐ **No**
7. Will the beneficiary **NOT** receive live vaccines during therapy? ☐ **Yes** ☐ **No**
8. Has the beneficiary had a trial and failure of Humira or a clinical reason beneficiary cannot try Humira? ☐ **Yes** ☐ **No**

Signature of Prescriber:_____ Date: _____

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.